{"log_id": 6378668284537554966, "direction": 0, "words_result_num": 27, "words_result": [{"probability": {"variance": 0, "average": 0.9995, "min": 0.999006}, "location": {"width": 100, "top": 124, "height": 29, "left": 164}, "words": "不同瘤种"}, {"probability": {"variance": 0.001449, "average": 0.987551, "min": 0.762653}, "location": {"width": 945, "top": 177, "height": 36, "left": 167}, "words": "在Ⅱ期研究中分别考察了在晚期结直肠癌患者(n=40)和晚期胃癌患者(n=12)的药代动力"}, {"probability": {"variance": 1e-05, "average": 0.998466, "min": 0.982489}, "location": {"width": 992, "top": 232, "height": 36, "left": 120}, "words": "学特征。晚期结直肠癌患者与同等剂量下健康受试者药代参数相似,而胃癌患者吸收延迟,暴"}, {"probability": {"variance": 2.1e-05, "average": 0.998221, "min": 0.974777}, "location": {"width": 993, "top": 288, "height": 37, "left": 118}, "words": "露水平更低。晚期胃癌患者对原发病灶的手术治疗(如胃大部切除术)以及整体的体质状况可"}, {"probability": {"variance": 5e-06, "average": 0.999126, "min": 0.99104}, "location": {"width": 318, "top": 344, "height": 30, "left": 119}, "words": "能会影响药物的的溶解和吸收"}, {"probability": {"variance": 0, "average": 0.999559, "min": 0.99914}, "location": {"width": 51, "top": 399, "height": 27, "left": 166}, "words": "分布"}, {"probability": {"variance": 2.7e-05, "average": 0.997083, "min": 0.973755}, "location": {"width": 945, "top": 450, "height": 34, "left": 166}, "words": "健康受试者单次空腹口服250mg,500mg和750mg甲磺酸阿帕替尼片后,平均表观分布容"}, {"probability": {"variance": 0.000939, "average": 0.989296, "min": 0.815358}, "location": {"width": 929, "top": 505, "height": 32, "left": 117}, "words": "积为929~2165L。用超滤法测得阿帕替尼血浆浓度在200ng/ml时的血浆蛋白结合率>86%"}, {"probability": {"variance": 0.000131, "average": 0.990088, "min": 0.974}, "location": {"width": 64, "top": 561, "height": 31, "left": 165}, "words": "代谢:"}, {"probability": {"variance": 0.000134, "average": 0.996486, "min": 0.919079}, "location": {"width": 942, "top": 615, "height": 31, "left": 164}, "words": "体外代谢酶研究表明阿帕替尼主要由CYP3A4代谢,其次经CYP2D6、CYP2C9和CYP2E1"}, {"probability": {"variance": 0.007025, "average": 0.971706, "min": 0.560344}, "location": {"width": 978, "top": 667, "height": 37, "left": 119}, "words": "代谢。在人体阿帕替尼主要经肝脏代谢,主要代谢途径为E-3-羟基化、Z-3-羟基化、25-N-氧"}, {"probability": {"variance": 0.004741, "average": 0.977168, "min": 0.719707}, "location": {"width": 789, "top": 724, "height": 31, "left": 116}, "words": "化、N去烷基化、16-羟基化、双羟基化及E-3-羟基化后O-葡萄糖醛酸结合"}, {"probability": {"variance": 0.004691, "average": 0.987541, "min": 0.544408}, "location": {"width": 945, "top": 777, "height": 32, "left": 162}, "words": "健康受试者单次口服750mg后,血浆中除原形外共检测到23个代谢产物,包括17个1相代"}, {"probability": {"variance": 0.003491, "average": 0.978975, "min": 0.699003}, "location": {"width": 992, "top": 830, "height": 33, "left": 116}, "words": "谢产物和6个Ⅱ相代谢产物,其中E-3-羟基阿帕替尼-O-葡萄糖醛酸结合物为循环中最主要的代"}, {"probability": {"variance": 5.5e-05, "average": 0.997725, "min": 0.954226}, "location": {"width": 995, "top": 883, "height": 36, "left": 114}, "words": "谢产物,其浓度高于原形药物,经检测没有明显的酪氨酸激酶抑制活性。其它主要代谢物浓度"}, {"probability": {"variance": 0, "average": 0.999694, "min": 0.999098}, "location": {"width": 173, "top": 939, "height": 29, "left": 115}, "words": "均低于原形药物"}, {"probability": {"variance": 0, "average": 0.99958, "min": 0.999381}, "location": {"width": 55, "top": 994, "height": 30, "left": 161}, "words": "排泄"}, {"probability": {"variance": 1.9e-05, "average": 0.997721, "min": 0.9824}, "location": {"width": 945, "top": 1047, "height": 31, "left": 163}, "words": "健康受试者单次口服750mg本品96小时后,检测到阿帕替尼及其主要代谢产物经粪和尿累"}, {"probability": {"variance": 4.6e-05, "average": 0.998272, "min": 0.956131}, "location": {"width": 993, "top": 1100, "height": 32, "left": 114}, "words": "积排泄量约为服药剂量的77%,其中经粪便的排泄量为剂量的698%高于尿中的排泄量"}, {"probability": {"variance": 0.000865, "average": 0.98888, "min": 0.855537}, "location": {"width": 953, "top": 1156, "height": 30, "left": 126}, "words": "7.02%),因此判断阿帕替尼口服给药后主要随粪便排泄。粪样中主要以原形排泄(59.0%)"}, {"probability": {"variance": 1e-06, "average": 0.99933, "min": 0.996619}, "location": {"width": 540, "top": 1211, "height": 29, "left": 113}, "words": "尿样中主要以代谢物形式排泄,原形几乎检测不到"}, {"probability": {"variance": 1e-06, "average": 0.999083, "min": 0.997959}, "location": {"width": 102, "top": 1266, "height": 29, "left": 161}, "words": "特殊人群"}, {"probability": {"variance": 3e-06, "average": 0.99868, "min": 0.993682}, "location": {"width": 637, "top": 1320, "height": 30, "left": 162}, "words": "尚未针对特殊人群如肝肾功能不全人群进行药代动力学研究"}, {"probability": {"variance": 1.9e-05, "average": 0.993899, "min": 0.988819}, "location": {"width": 81, "top": 1365, "height": 27, "left": 124}, "words": "【贮藏】"}, {"probability": {"variance": 0, "average": 0.999369, "min": 0.997996}, "location": {"width": 298, "top": 1409, "height": 31, "left": 162}, "words": "遮光、密封,25℃以下保存"}, {"probability": {"variance": 1e-06, "average": 0.999368, "min": 0.998138}, "location": {"width": 83, "top": 1462, "height": 29, "left": 122}, "words": "【包装】"}, {"probability": {"variance": 0.000802, "average": 0.991625, "min": 0.864826}, "location": {"width": 919, "top": 1508, "height": 34, "left": 162}, "words": "聚酰胺/铝/聚氯乙烯冷冲压成型固体药用复合硬片和药品包装用铝箔热合密封的双铝板"}], "language": 3}